上海交通大学医学院位于创新求索、文化荟萃、包容并蓄的黄浦腹地，红墙映日、梧桐环绕。其前身是由圣约翰大学医学院(1896-1952)、震旦大学医学院(1911-1952)、同德医学院（1918-1952)于1952年全国高等学校院系调整时合并而成的上海第二医学院，1985年更名为上海第二医科大学。1997年学校通过了“211工程”立项。2005年7月，上海交通大学与上海第二医科大学合并，成立了新的由教育部、上海市政府重点共建的上海交通大学医学院，进入“985”高校行列。2010年11月，学院成为卫生部与教育部合作共建的第一批十个重点高校中的一员。
We're tracking Shanghai Jiao Tong University School Of Medicine's market expansion
How Shanghai Jiao Tong University School Of Medicine's international expansion compares to its competitors
Shanghai Jiao Tong University School Of MedicineYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Shanghai Jiao Tong University School Of MedicineYou | 0 | 0 | — | 0 | 0 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
MUST study and its subgroup analyses provide evidence for Musk Xiang Bao Xin Wan's efficacy in treating coronary artery disease, showing improved quality of life and reduced cardiovascular events.
Heyuan Biotech's CAR-T cell therapy Najierlongcell Injection approved in China for treating relapsed/refractory large B-cell lymphoma, marking its second indication after leukemia.
Heyuan Biotech's CAR-T therapy Natukleucel approved in China for r/r LBCL, becoming the first domestic product covering both leukemia and lymphoma indications.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Shanghai Jiao Tong University School Of Medicine's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
